Kevin Dolowy Dalgaard Email & Phone Number

Copenhagen, Capital Region, DK

Lundbeckfonden BioCapital is an evergreen venture capital fund that invests in life science companies, supporting the translation and commercialization of ground-breaking science.

Copenhagen, DK

Notify Therapeutics focuses on the initial ovarian follicle development, in the hormone-independent phase, to help infertile women that do not benefit from today’s standard hormone treatment.

Leiden, NL

VarmX is a drug development company, developing drugs to restore haemostasis in case of bleeding or emergency surgery in patients taking oral factor Xa inhibitors.

Hørsholm, DK

AFYX Therapeutics is a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options.AFYX acquired by Inphena in January 2024.

Ingelheim Am Rhein, Rhineland-Palatinate, DE

• Leading global licensing activities for CardioMetabolism and Retinal Health, ranging from search and evaluation of opportunities, internal approval to enabling business negotiations and deal execution
• Development and implementation of licensing and partnering strategy based on the overall TA strategies

Bagsværd, DK

• Portfolio manager for new anti-diabetics: Driving innovation, external sourcing, stakeholder management, and preparation of reports and presenting for upper management.
• Involved in due diligences, initiation of strategic partnerships, in-licensing deals and research collaborations.
• Commercial assessment of early projects including preparation of Target Product Profiles (TPPs), strategic fit and commercial attractiveness assessments and valuations.
• Planning and driving pre-clinical research projects within Type 2 Diabetes.

Bagsværd, DK

• GLP-1 & T2D Pharmacology
• Project management of pre-clinical research with focus on T2DM.
• In vivo pharmacology: Setting objectives, execution and realization ofresearch plans to support anti-diabetes portfolio.

Freiburg Im Breisgau, Baden-Württemberg, DE

• Epigenetic Control of Metabolic DiseasesLab: Dr. J. Andrew PospisilikObjective: Understand how environmental cues influence metabolic diseases (diabetes, obesity).
• Planning, organising and designing rodent experiments.
• In vivo metabolic phenotyping (indirect calorimetry, telemetry, OGTT, ITT).
• Pharmacological and dietary interventions.
• NGS-sequencing (ChIP-seq, RNA-seq, MeDIP-seq, WGBS/RRBS-seq).
• NGS data analysis (R, Tophat, Bowtie, Cufflinks, DESeq, Bismark, MACS).

Freiburg Im Breisgau, Baden-Württemberg, DE

As a PhD representative I represented the other PhD students by effectively communicating between them and administrators. Furthermore, I organised several social events, PhD meetings and actively participated in the screening and selection of new PhD candidates for the IMPRS doctoral programme.

Cambridge, England, GB

As a part of a collaboration, I worked in the lab of Prof. Anne Ferguson-Smith to get hands-on experience with quantitative bisulfite pyrosequencing for quantitative assessment of DNA methylation levels of imprinting control regions.

Stavanger, Rogaland, NO

Biochemical characterization of recombinantly expressed proteins involved in DNA repair using "hot"-reagents. Lab: Professor Svein Bjelland.

København K, DK

Supervision of undergraduate students.

Doctor Of Philosophy (Ph.D.), Molecular Biology

Master Of Science, Biochemistry

Bachelor Of Science (Bsc), Biochemistry